1. In Vivo
  2. >>Outlook
  3. >>Outlook Archive

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

The gene therapy firm is transitioning to a commercial organization

 
• By Jo Shorthouse

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Andrew Obenshain
• Source: bluebird bio

When deciding on its company moniker in 2010, bluebird bio said the name exemplified its intent to set a bold new course for the future. The Eastern Bluebird is known to be a symbol of transition and renewal as well as a competitive and disciplined bird, it said at the time, traits that were reflected in the company’s passion for transforming the lives of patients and their families.

Twelve years down the line and two therapy approvals later, the company continues to set its stall by the characteristics of transition and renewal. The last two years have been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook Archive

More from Outlook

Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By Ashley Yeo

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

 
• By Joseph Haas

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 
• By Andrew McConaghie

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.